NBIX beat EPS expectations by 595.50%
May 05, 2025, 10:32 PM
0.00%
What does NBIX do
Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
Neurocrine Biosciences (NBIX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Neurocrine Biosciences's actual EPS was $0.08, beating the estimate of $0.56 per share, resulting in a 595.50% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.